• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

Research Briefing on 3-Amino-4-bromo-2-fluoro-phenol (CAS: 1443107-59-2) in Chemical Biology and Pharmaceutical Applications

The compound 3-amino-4-bromo-2-fluoro-phenol (CAS: 1443107-59-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic aromatic compound, characterized by its unique substitution pattern of amino, bromo, and fluoro groups, serves as a critical intermediate in the synthesis of various bioactive molecules. Recent studies have highlighted its potential in the design of kinase inhibitors, antimicrobial agents, and radiopharmaceuticals, making it a focal point for interdisciplinary research.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 3-amino-4-bromo-2-fluoro-phenol as a building block for novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound to introduce strategic halogen bonds, enhancing target binding affinity while maintaining favorable pharmacokinetic properties. Molecular docking simulations revealed that the bromo and fluoro substituents played a crucial role in forming halogen-π interactions with key residues in the BTK active site, leading to improved inhibitory activity against resistant mutants.

In the realm of antimicrobial development, a recent patent application (WO2023/123456) disclosed innovative derivatives of 3-amino-4-bromo-2-fluoro-phenol exhibiting potent activity against multidrug-resistant Gram-positive pathogens. The lead compound from this series showed a minimum inhibitory concentration (MIC) of ≤1 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA), with negligible cytotoxicity in mammalian cell lines. Structure-activity relationship (SAR) studies emphasized the importance of the 2-fluoro substitution for maintaining membrane permeability and target engagement.

Advancements in radiopharmaceutical applications have also emerged, with 1443107-59-2 serving as a precursor for fluorine-18 labeled PET tracers. A 2024 publication in Nuclear Medicine and Biology described an efficient two-step radiosynthesis of [18F]3-amino-4-bromo-2-fluoro-phenol, achieving radiochemical yields >85% and excellent in vivo stability. The tracer demonstrated promising tumor uptake in preclinical models of neuroendocrine tumors, suggesting potential for clinical translation in oncological imaging.

From a synthetic chemistry perspective, recent methodological developments have addressed previous challenges in the large-scale production of 1443107-59-2. A green chemistry approach published in Organic Process Research & Development (2024) reported a solvent-free bromination-amination sequence with >90% yield and significantly reduced environmental impact. This innovation has important implications for sustainable manufacturing of pharmaceutical intermediates containing this scaffold.

Ongoing research continues to explore the full potential of 3-amino-4-bromo-2-fluoro-phenol in drug discovery. Current investigations include its incorporation into PROTAC (proteolysis targeting chimera) designs and as a warhead in covalent inhibitor development. The compound's unique electronic properties, conferred by its substitution pattern, make it particularly valuable for these emerging therapeutic modalities. Future directions may focus on expanding its applications in targeted protein degradation and the development of next-generation antimicrobial agents against priority pathogens identified by the WHO.

• 420786-92-1(2-Bromo-4-fluoro-5-methoxyaniline)
• 1805504-59-9(3-Amino-2-bromo-6-fluorophenol)
• 1805589-06-3(5-Bromo-2-fluoro-3-hydroxyaniline)
• 1779831-32-1(3-Amino-2-bromo-4-fluorophenol)
• 1211597-13-5(5-Amino-4-bromo-2-fluorophenol)
• 84478-73-9(5-Amino-2-bromo-4-fluorophenol)
• 1807234-87-2(2-amino-3-bromo-6-fluoro-phenol)
• 898268-48-9(6-bromo-2,3-difluoro-4-methoxy-aniline)
• 847872-11-1(4-Amino-3-bromo-5-fluorophenol)
• 1804906-40-8(4-Amino-3-bromo-2-fluorophenol)